Markets:

Overview

News

Currencies

International

Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

8.750 +0.010 (+0.11%)

Streaming Delayed Price Updated: 11:37 AM EDT, Jun 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Dual-Antibody Cocktail Shows Effectiveness In COVID-19 Animal Models: Reuters ↗

June 22, 2021

In mice and hamster study, COVID-19 therapies comprising two types of antibodies were found to be effective against a wide range of COVID-19 variants, Reuters reported ...

Via Benzinga

GSK - Vir Biotech's Sotrovimab Reduces Hospitalization, Risk Of Death In Adult COVID-19 Patients ↗

June 21, 2021

GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced final, confirmatory results from the Phase 3 COMET-ICE evaluating...

Via Benzinga

The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs ↗

June 20, 2021

Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries.

Via Talk Markets

The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs ↗

June 20, 2021

Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal...

Via Benzinga

Earnings Scheduled For May 6, 2021 ↗

May 06, 2021

Companies Reporting Before The Bell • ViacomCBS (NASDAQ:VIAC) is projected to report quarterly earnings at $1.22 per share on revenue of $7.30 billion. • Cohen...

Via Benzinga

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗

May 01, 2021

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...

Via Benzinga

15 Words From Vir Biotechnology's CEO May Mean Market Dominance ↗

June 02, 2021

Vir's antibody treatment is addressing one of the biggest COVID challenges.

Via The Motley Fool

The Surprising Move Vir Stock Made After Winning Covid Drug Authorization ↗

May 27, 2021

GlaxoSmithKline and Vir Biotechnology won Food and Drug Administration authorization for a Covid treatment on Wednesday, but Vir stock slipped Thursday.

Via Investor's Business Daily

Vir Biotech Stock Jumps After FDA Emergency Use Approval COVID-19 Antibody Drug ↗

May 27, 2021

The FDA has given an emergency use authorization (EUA) to COVID-19 antibody treatment developed by Vir Biotechnology Inc (NASDAQ: VIR) and ...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 27, 2021

Gainers Zosano Pharma (NASDAQ:ZSAN) stock moved upwards by 22.59% to $0.91 during Thursday's pre-market session. The company's market cap stands at $97.3 million....

Via Benzinga

The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs ↗

May 27, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)...

Via Benzinga

24 Stocks Moving in Thursday's Pre-Market Session ↗

May 27, 2021

Gainers Vertex Energy, Inc. (NASDAQ: VTNR) rose 82% to $3.24 in pre-market trading after the company announced plans to acquire a Alabama refinery and related logistics assets....

Via Benzinga

Market Briefing For Thursday, May 27 ↗

May 27, 2021

Dynamics spurring last year's upside, mostly sputtered with sector-rotation since early February. Periodically breadth broadens out slightly and a move in unison occurs, absent sustainability.

Via Talk Markets

GlaxoSmithKline - Vir Biotech's Antibody COVID-19 Treatment Wins CHMP's Positive Scientific Opinion ↗

May 21, 2021

The European Medicines Agency’s advisory group, Committee for Human Medicinal Products (CHMP), has concluded that GlaxoSmithKline plc (NYSE: GSK) and Vir...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

May 10, 2021

Gainers Vir Biotechnology (NASDAQ:VIR) sha...

Via Benzinga

Bill And Melinda Gates' Divorce News A Bull Case For GameStop? What You Need To Know ↗

May 04, 2021

A post by a member of the Reddit investor forum r/GME in March that speculated billionaires were increasing their short positions in GameSt...

Via Benzinga

Brii Biosciences, Vir Biotech, VBI Vaccines Start Combination Therapy Hepatitis B Study ↗

April 21, 2021

Privately-held Brii Biosciences, Vir Biotechnology Inc (NASDAQ: VIR), and VBI Vaccines Inc (NASDAQ: VBIV) have dosed the first patient...

Via Benzinga

The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs ↗

May 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:...

Via Benzinga

The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom ↗

May 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B

April 21, 2021

From Brii Biosciences and Vir Biotechnology, Inc. and VBI Vaccines Inc.

Via Business Wire

Could Vir Biotechnology Be a Millionaire Maker Stock? ↗

April 17, 2021

Vir is developing treatments in billion-dollar markets.

Via The Motley Fool

Which Stock Is Likely to Be the Biggest Winner: Lilly, Vir, or GlaxoSmithKline? ↗

April 10, 2021

One of the three clearly has the most upside potential.

Via The Motley Fool

Vir Biotechnology vs. Sorrento Therapeutics: The Wisdom of Crowds Says... ↗

April 08, 2021

Which stock has more potential for growth over the next year? Let's look to the stars for an answer.

Via The Motley Fool

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.